STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
04/03/2026
01/02/2026
09/26/2025
06/27/2025
03/28/2025
Revenue
290
93
57
94
44
42
Revenue Growth (YoY)
--
111%
36%
7%
-56%
-45%
Cost of Revenue
67
24
14
16
11
14
Gross Profit
223
68
43
77
32
28
Selling, General & Admin
178
41
45
44
47
49
Research & Development
38
9
9
9
10
13
Operating Expenses
217
51
54
53
57
62
Other Non Operating Income (Expenses)
2
0
1
0
0
0
Pretax Income
-19
8
-20
18
-25
-54
Income Tax Expense
1
3
-2
9
-9
0
Net Income
-21
5
-18
8
-16
-54
Net Income Growth
--
-131%
-67%
-11%
-329%
1,700%
Shares Outstanding (Diluted)
50.9
50.9
49.77
50.54
49.52
49.34
Shares Change (YoY)
--
3%
1%
2%
-1%
1%
EPS (Diluted)
-0.42
0.1
-0.36
0.17
-0.33
-1.09
EPS Growth
--
-130%
-67%
-12%
-329%
1,508%
Free Cash Flow
-54
-22
-5
1
-29
-7
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
76.89%
73.11%
75.43%
81.91%
72.72%
66.66%
Operating Margin
2.06%
18.27%
-17.54%
25.53%
-54.54%
-80.95%
Profit Margin
-7.24%
5.37%
-31.57%
8.51%
-36.36%
-128.57%
Free Cash Flow Margin
-18.62%
-23.65%
-8.77%
1.06%
-65.9%
-16.66%
EBITDA
14
19
-8
26
-23
-32
EBITDA Margin
4.82%
20.43%
-14.03%
27.65%
-52.27%
-76.19%
D&A For EBITDA
8
2
2
2
1
2
EBIT
6
17
-10
24
-24
-34
EBIT Margin
2.06%
18.27%
-17.54%
25.53%
-54.54%
-80.95%
Effective Tax Rate
-5.26%
37.5%
10%
50%
36%
0%
Follow-Up Questions
What are STAAR Surgical Co's key financial statements?
According to the latest financial statement (Form-10K), STAAR Surgical Co has a total asset of $0, Net loss of $0
What are the key financial ratios for STAA?
STAAR Surgical Co's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is STAAR Surgical Co's revenue broken down by segment or geography?
STAAR Surgical Co largest revenue segment is ICLs, at a revenue of 312,543,000 in the most earnings release.For geography, Domestic is the primary market for STAAR Surgical Co, at a revenue of 22,558,000.
Is STAAR Surgical Co profitable?
no, according to the latest financial statements, STAAR Surgical Co has a net loss of $0
Does STAAR Surgical Co have any liabilities?
no, STAAR Surgical Co has liability of 0
How many outstanding shares for STAAR Surgical Co?
STAAR Surgical Co has a total outstanding shares of 0